Help for liver transplant patients with small-for-size syndrome
February 3, 2009Blocking off the splenic artery, either through surgical ligation or radiological coiling, helped six out of seven patients suffering from small-for-size syndrome after a partial liver transplant. This finding is in the February issue of Liver Transplantation.
Due to the shortage of liver donors, and the long list of patients in need of a transplant, doctors are increasingly using partial grafts. They may take half of the liver from a living donor, or split the liver of a deceased donor into two usable parts. These techniques have increased the number of transplants being performed; however, they have also led to new problems, such as small-for-size syndrome (SFSS), in which the new liver can't handle the metabolic demands of the recipient.
The syndrome causes liver dysfunction soon after the transplant; symptoms include problems with bile flow and coagulation, and ascites, which is the accumulation of fluid in the abdomen. Without treatment, about 50 percent of patients with SFSS will die of sepsis or another complication. Fortunately, there are ways to treat the condition, although the best approach is unclear.
To examine possible treatments for SFSS, researchers, led by Abhinav Humar of the University of Minnesota, conducted a retrospective database analysis of all adult recipients of partial liver transplants at their center between 1997 and 2007. There were 100 such patients, seven of whom developed SFSS. Five of the seven underwent additional abdominal surgery within two weeks of their transplant, to rule out a technical complication of the transplant, and then to have their splenic artery ligated. The other two patients were treated radiologically by splenic artery coiling.
"Of the seven recipients, six had a good response to the splenic artery occlusion with improvement of liver function tests over the course of the next one to two weeks," the authors report. None developed post-operative spleen infections and all were alive and well after an average follow-up time of three years. One of the patients treated radiologically did not improve, and required a new transplant, which he received three months later.
The doctors at the center eventually altered their approach in an attempt to prevent SFSS before it could happen. They performed splenic artery ligation at the time of transplantation in patients who had high portal vein pressure.
While prevention of SFSS should be the goal, they say, this study indicates that occluding the splenic artery is a reasonable approach for treatment of established SFSS. "All except one of our recipients seemed to have a favorable response, and eventual complete normalization of their liver function tests," they report.
An accompanying editorial by Chung Mau Lo of Hong Kong, emphasizes the need for a consensus on how to diagnose SFSS. As for treating this condition, he supports the conclusions of Humar and colleagues.
He advocates routine monitoring of portal pressure and flow in high-risk partial liver transplant recipients. "Portal flow modulation such as splenic artery ligation should be done early rather than delayed," Lo writes.
The article is available online at Wiley Interscience (www.interscience.w … ce.wiley.com).
Article: "Delayed Splenic Artery Occlusion for Treatment of Established Small-for-Size Syndrome after Partial Liver Transplant." Humar, Abhinav; Beissel, Joy; Crotteau, Shaina; Cohen, Melissa; Hill, Mark; Lake, John; Payne, William. Liver Transplantation ; February 2009.
Editorial: "Splenic Artery Occlusion for Small-for-Size Syndrome—Better Late Than Never But Early Is the Best." Lo,Chung Mau. Liver Transplantation; February 2009.
Source: Wiley-Blackwell
-
Some donor factors affect outcomes for HCV-positive liver transplant recipients
May 28, 2009 |
not rated yet |
0
-
Double hand transplant patient recovering well
May 08, 2009 |
not rated yet |
0
-
Grapefruit juice boosts drug's anti-cancer effects
Apr 20, 2009 |
4.6 / 5 (7) |
1
-
'Stimulated' stem cells stop donor organ rejection
Oct 18, 2011 |
3.8 / 5 (5) |
2
-
High-risk donor livers used with greater frequency in transplantations
Sep 28, 2011 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (30) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Team isolates nerve cells involved in storing long term memory and gene proteins associated with them
(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...
News of plaque-clearing drug tops week of major advances against Alzheimer's disease
In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...
51 minutes ago |
not rated yet |
1
To avoid early labor and delivery, weight and diet changes not the answer
One of the strongest known risk factors for spontaneous or unexpected preterm birth any birth that occurs before the 37th week of pregnancy, most often without a known cause is already having had one. For women ...
4 minutes ago |
not rated yet |
0
|
Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease
St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.
20 minutes ago |
not rated yet |
0
S.Africa in $208 mln AIDS drug venture with Swiss Lonza
South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.
Medicine & Health / HIV & AIDS
1 hour ago |
not rated yet |
0
The power of estrogen -- male snakes attract other males
A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...
Could Venus be shifting gear?
(PhysOrg.com) -- ESAs Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...
Experts reveal how plants don't get sunburn
(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.
Fool's gold may prove an unlikely alternative to overexploited catalytic materials
Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...
SLAC, Stanford team focuses on high-energy electrons to treat cancer
Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...
Unpicking HIV’s invisibility cloak
Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel targetits camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...